As quoted in the press release from Cipla and Eli Lilly, the companies will launch tirzepatide under the brand “Yurpeak” in India with six dosage strengths (2.5–15 mg) and pricing aligned with Mounjaro. The deal places Cipla in a marketing role while Lilly manufactures.
Source: Cipla Limited Press Release (NSE Exchange Filings) | Published on Oct 23, 2025
Disclaimer: This content has been published for informational purposes only. Bajaj Broking is not affiliated with, nor does it endorse or assume any responsibility for, the source material. Readers are advised to consult the original publication for complete and accurate context.
As quoted in the press release from Cipla and Eli Lilly (NSE Exchange Filings), the companies have entered into an agreement to market the drug tirzepatide in India under the brand name “Yurpeak”. This deal involves Cipla taking up the marketing rights while Eli Lilly continues manufacturing. The partnership covers six dose strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg) and pricing is set at the same level as the current brand in India.
Cipla and Eli Lilly said on 23 October 2025 that Eli Lilly will manufacture tirzepatide, and Cipla will market and distribute the drug in India under the new brand name Yurpeak.
The drug is indicated for diabetes and obesity management and forms part of the class of therapies known as GIP/GLP-1 dual receptor agonists.
Also read: Hero MotoCorp Enters UK Market With MotoGB Tie-Up
Feature | Detail |
Active Ingredient | Tirzepatide |
Brand Name in India | Yurpeak |
Marketing Partner | Cipla |
Manufacturing Partner | Eli Lilly |
Dose Strengths | |
Pricing | Set equal to Mounjaro in India |
As of 23 October 2025, 15:30 IST, Cipla Ltd’s share price on the NSE stood at ₹1,645.00, marking a decline of ₹ 18.60 (1.12%) from the previous close of ₹ 1,663.60.
Tirzepatide, a GIP/GLP-1 dual receptor agonist, has been studied and demonstrated cardiovascular and metabolic benefits in international trials.
The partners have indicated that the product will launch under Yurpeak once local regulatory approvals are in place. Eli Lilly had earlier signalled its intent to launch its Mounjaro version in India by 2025. Supply will remain with Eli Lilly’s manufacturing infrastructure, while Cipla will manage distribution and promotion.
Also read: BLS International Secures Visa Service Contracts in Kazakhstan & China
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading